Palisade Capital Management’s Chemomab Therapeutics CMMB Stock Holding History

Palisade Capital Management’s Portfolio CMMB Stock Details CMMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,776	Closed	-$421K	–	387
2020 Q3	$421K	Hold	5,776	–	–	0.01%	342
2020 Q2	$506K	Hold	5,776	–	–	0.02%	331
2020 Q1	$291K	Hold	5,776	–	–	0.01%	376
2019 Q4	$517K	Hold	5,776	–	–	0.01%	354
2019 Q3	$850K	Hold	5,776	–	–	0.03%	339
2019 Q2	$1.66M	Buy	+5,776	New	+$2.01M	0.05%	302

Other funds holding CMMB

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

RegentAtlantic Capital Morristown, New Jersey $3.34B AUM 14.54% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Palisade Capital Management's CMMB Position: Q4 2020 in Review

Palisade Capital Management sold out of Chemomab Therapeutics (CMMB) in Q4 2020, closing a stake of 5,776 shares — an estimated $421K sold.

Palisade Capital Management first reported a position in CMMB in Q2 2019 and held it in 6 quarters. The position peaked at $1.66M in Q2 2019. 5 funds tracked by Wall St. Rank hold CMMB as of Q4 2020.

Palisade Capital Management reported no remaining Chemomab Therapeutics position as of Q4 2020 after selling out during the quarter.
Palisade Capital Management sold 5,776 Chemomab Therapeutics shares in Q4 2020, an estimated $421K.
Palisade Capital Management first reported a position in Chemomab Therapeutics in Q2 2019 and held it in 6 quarters.
Palisade Capital Management's Chemomab Therapeutics position peaked at $1.66M in Q2 2019.
5 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q4 2020.

Based on Palisade Capital Management's 13F filing for Q4 2020, filed 11 Feb 2021.